IOVANCE BIOTHERAPEUTICS, INC. — Director's Dealing 2021

Jun 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK: 0001425205
Period of Report: 2021-06-14

Reporting Person: Bellemin Jean-Marc (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-14	Restricted Stock Units	$	A	37700	Acquired		Common stock (37700)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units vest as follows: (i) one-half of such shares shall vest and be settled on the one-year anniversary of the date of grant; and (ii) the remaining shares shall vest and be settled on December 31, 2022.